Sustainable Solutions
Nova™ Platform is a cost-effective reusable system with no recurring costs for your research.
Modular
Design
Easily add dilution or mixer modules to expand system functionality.
Ease and Reliability
Save protocols, make NPs (0.2 mL to >100 mL) of uniform size (50-150nm), PDI (<0.2), and high encapsulation efficiency (>90%).
Scalable
Design
Increase production capacity using the same proven mixing principles with the Nova™ Pilot High Throughput (HT) system.
Regulatory Compliant
Comprehensive data management, GMP ready and 21 CFR part 11 compliant.
Nova™ Benchtop
Designed for Lipid Nanoparticle R&D and Pre-Clinical Development
Wide sample volume range: easily produce low sample volumes of 200 μL and >100 mL on a single instrument. Easily pool sample runs for larger volumes.
Add modules as you go: streamline your nanoparticle work flow as needed. The Nova™ BT evolves with you.
Nova™ BT system with additional in-line dilution modules
Software and PC Control
Custom User Interface
Monitor and control formulation
via PC or laptop.
Formulation Optimization - Common Easily Tunable Parameters
-
TFR - Total Flow Rate (0.1 to 100 mL/min)
-
FRR - Flow Rate Ratio
-
Process Startup/End Wastes, Priming Volumes
-
Mixer Size
Scalable LNP Manufacturing
Solutions with Nova™IJM
1
2
3
Scale Up, Not Scale Out: The IJM approach allows for greater flow rates and thus LNP production. Reynolds number helps us predict the ideal flow rates for a desired production capacity.
Flexible Technology: Readily increase flow rates by changing the syringe pump modules with continuous pump modules, keeping the same mixing principles from small to large scale.
Optimize and Monitor: Utilize integrated sensors and real-time analytics within the Nova Pilot HT system to continuously monitor critical parameters such as pressure and flow rates. GMP and 21 CFR Part 11 compliant.
Increase production output with continuous pump modules
Continuous Pump
Size 5 Mixer has an ideal flow rate of 410 mL/min
Proven Performance in Vaccine Development
Data provided by
Dr. Debbie Burnett
Vaccines produced by the Nova™ can achieve immunogenicity profiles comparable to or better than those of leading commercial vaccines.
Visualize your cargo biodistribution with LNPs made by the Nova™
FLuc mRNA-LNP - IV
FLuc mRNA-LNP - IM
PBS Control - IV
